ABIOMED -ABMD- 873886- Interessantes Biotechunternehmen

Beiträge: 3
Zugriffe: 168 / Heute: 1
ABIOMED -ABMD- 873886- Interessantes Biotechunternehmen tgk1

ABIOMED -ABMD- 873886- Interessantes Biotechunternehmen

01.03.00 10:19
KOnzentrieren sich auf die Herstellung von künstlichen Herzen.
Enormes Potential, weil es nicht genügend Spenderherzen gibt, und es zu keiner negativen Reaktion auf ein fremdes Organ des Körpers kommen kann.


Hat sich schon jemand von euch mit dem Wert beschäftigt, denke da an Kicky, Kaeseotto und Lalapo.......

Würde mich über Antworten freuen.
ABIOMED -ABMD- 873886- Interessantes Biotechunternehmen tgk1

Kapiatalerhöhung um 98 Mill $ ; Limit 68 euro; aktuell 76

01.03.00 10:37
BusinessWire, 03/1/2000 01:02

                                 ABIOMED Announces Pricing of Public Stock Offering

                                 DANVERS, Mass.--(BUSINESS WIRE)--March 1, 2000--ABIOMED, Inc. (NASDAQ:ABMD) announced today that it has
                                 priced a public offering of 1,500,000 shares of its common stock. The offering price was $68.00 per share resulting in net
                                 proceeds to the Company of approximately $95 million.

                                 All 1,500,000 shares are being offered by the Company. The Company and one shareholder together have also granted
                                 to the underwriters a 30-day option to purchase up to 225,000 shares solely to cover over-allotments.

                                 The Company expects to use the net proceeds of this offering for funding of initial clinical trials of the AbioCor(TM) Implantable Replacement Heart, continued

                                 research and development, expansion of manufacturing capabilities, international sales and marketing and other general corporate purposes, including
                                 potential acquisitions. The managing underwriters for the offering were Banc of America Securities LLC and Salomon Smith Barney. The offering is scheduled
                                 to close on March 6, 2000.

                                 Copies of the final prospectus for the offering may be obtained from Banc of America Securities LLC, 600 Montgomery Street, San Francisco, California
                                 94111 or Salomon Smith Barney Inc., 140 58th Street, Brooklyn, New York 11222.

                                 Based in Danvers, Massachusetts, ABIOMED, Inc. is a leading developer, manufacturer and marketer of medical products designed to assist or replace the
                                 pumping function of the failing heart.

                                 Certain statements contained in this press release, including statements regarding the anticipated timing of the closing of the offering and the use of
                                 proceeds and other statements contained herein regarding matters that are not historical facts, are "forward-looking" statements (as such term is defined in
                                 the Private Securities Litigation Reform Act of 1995). Because such statements are subject to risks and uncertainties, actual results may differ materially from
                                 those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by
                                 such forward-looking statements include, but are not limited to, those factors discussed in the section entitled "Risk Factors" in the Company's Registration
                                 Statement on Form S-3 filed with the SEC on December 17, 1999, as amended.  
ABIOMED -ABMD- 873886- Interessantes Biotechunternehmen Eskimato

Ist Euch bestimmt auch aufgefallen,

mit AdHoc von heute, Gruss E.


FDA Approves ABIOMED's New AB5000 Heart Assist Ventricle  
       THURSDAY, SEPTEMBER 25, 2003 11:58 AM
- BusinessWire

DANVERS, Mass., Sep 25, 2003 (BUSINESS WIRE) -- ABIOMED, Inc., (ABMD) announced today that it has received FDA approval to begin commercial distribution of the Company's new AB5000(TM) Ventricle, the first in a planned series of additions to its new AB5000(TM) heart assist product line. The AB5000 Ventricle can provide temporary support for one or both sides of the natural heart in circumstances where the heart has failed but has the potential to recover. It is driven and controlled by the AB5000(TM) Circulatory Support System Console that ABIOMED recently introduced into the U.S. market.

"The AB5000 Ventricle is an exciting addition to our product offerings," said Gene Rabe, Senior Vice President for Sales and Services. "It will provide significant benefits to patients with regard to mobility and comfort, and should thereby aid the process of recovery. In conjunction with the AB5000 Console, the new Ventricle provides a total circulatory support system that we believe will provide the ease of use and reliability that our physician and hospital customers have told us they value. Our research tells us that the AB5000 Ventricle should be well-received in the market, and our sales force is eager to begin introducing it to their accounts."

"Approval of the AB5000 Ventricle, following the recent FDA approval and introduction of ABIOMED's new AB5000 Console, is an important business milestone for ABIOMED," said Chief Executive Officer Dr. David M. Lederman. "This is our first significant addition to our commercial product portfolio since the original introduction of the BVS(R) product line, and it solidifies the new AB5000(TM) platform as one focal point for our growth over the next year and beyond. This example of successful execution of one of our business objectives exemplifies the commitment to commercial success of dozens of members of our product development, clinical and regulatory teams. They executed with excellence in record time.

"In April of this year," Lederman continued, "we announced an ambitious program timetable of product introductions planned for the next several years, including those related to the AbioCor(R) Implantable Replacement Heart. Today's announcement of a critical regulatory approval for our new product platform demonstrates that we are executing according to that timetable. We intend to continue to meet those milestones, and our entire organization remains focused on that purpose."

Based in Danvers, Massachusetts, ABIOMED, Inc. (pronounced "AB'-EE-O-MED") is a leading developer, manufacturer and marketer of medical products designed to assist or replace the pumping function of the failing heart. ABIOMED, which currently sells the BVS 5000(R) Biventricular Support System and the AB5000 Circulatory Support System, is the market leader in devices for the temporary support of patients with failing but potentially recoverable hearts. The Company's first generation AbioCor Implantable Replacement Heart is the subject of an initial clinical trial being conducted under an Investigational Device Exemption from the United States Food and Drug Administration. The AbioCor has not been approved for commercial distribution, and is not available for use or sale outside of the initial clinical trial.

This Release contains forward-looking statements, including statements regarding the likely market acceptance of the AB5000 Ventricle, the future market introduction of additional new circulatory support and heart replacement products, and ABIOMED's future performance. ABIOMED's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, anticipated future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, future capital needs and uncertainty of additional financing and other risks detailed in the Company's filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this Release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this Release or to reflect the occurrence of unanticipated events.


Edward E. Berger, Ph.D., 978-646-1419
Investor Relations:
Lippert/Heilshorn & Associates, Inc.
Kim Sutton-Golodetz, 212-838-3777
Bruce Voss, 310-691-7100

Börsenforum - Gesamtforum - Antwort einfügen - zum ersten Beitrag springen